Povezanost nivoa adiponektina i rezistina u serumu sa ozbiljnošću jetrene fibroze kod pacijenata sa hroničnim hepatitisom B

  • Nerma Čustović University Clinical Center Sarajevo, Gastroenterohepatology department
  • Senija Rašić
DOI: https://doi.org/10.5937/jomb0-33793
Ključne reči: adipocitokini, APRI, FIB-4, hepatitis B

Sažetak


Uvod: Novija istraživanja usko su povezala adipocitokine sa progresijom upale i fibroze jetre u bolesnika sa bezalkoholnom bolesti jetre. Cilj ovog istraživanja bio je utvrditi odnos serumskog nivoa adiponektina i rezistina sa težinom fibroze jetre u pacijenata sa hroničnim hepatitisom B (CHB), ovisno o trajanju antivirusne terapije.

Metode:Presečna studija obuhvatila je 75 pacijenata sa HHB podeljenih u dve grupe: T1 grupa (na antivirusnoj terapiji do 2 godine) i T2 grupa (na antivirusnoj terapiji preko 2 godine). Kontrolnu grupu činilo je 40 zdravih osoba. Serumske koncentracije adiponektina I rezistina procenjene su ELISA metodom, dok je stepen fibroze jetre određen pomoću FIB-4 i APRI skora.

Rezultati:Više vrednosti koncentracije rezistina u serumu potvrđene su u pacijenata sa HHB u poređenju sa zdravim kontrolama. Srednji nivo serumskog rezistina bio je značajno viši u grupi pacijenata sa većim FIB-4 skorom (9.12 ± 3.39 prema 5.58 ± 3.36 ng/mL, p = 0.001), kao I većim APRI skorom (17.45 ± 3.96ng/mL prema 4.82 ± 1.11 ng/mL, p = 0.001). Nađena je pozitivna korelacija između serumskog nivoa rezistina i stepena fibroze jetre (p <0.001). Nije bilo značajne razlike između prosečnih serumskih nivoa adiponektina u odnosu prema vrednostima FIB-4 i APRI skora.

Zaključak:Koncentracija rezistina u serumu mogla bi biti potencijalni neinvazivni biomarker  ozbiljnosti fibroze jetre u pacijenata sa hroničnim hepatitisom B na antivirusnoj terapiji.

Reference

1. Fang H, Judd RL. Adiponectin regulation and function. ComprPhysiol 2018; 8: 1031-63. DOI: 10.1002/cphy.c170046
2. Senesi P, LuziL,TerruzziI. Adipokines, myokines, and cardiokines: the role of nutritional interventions. Int J MolSci 2020; 21: 8372. DOI: 10.3390/ijms21218372
3. Chang ML, YangZ,Yang SS.Roles of adipokines in digestive diseases: Markers of inflammation, metabolic alteration and disease progression.Int J MolSci 2020;21 :8308. DOI: 10.3390/ijms21218308
4. AcquaroneE, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: areappraisal.Mech Ageing Dev 2019;178:46-63. DOI: 10.1016/j.mad.2019.01.004
5. Arunkumar EA, Sushil KJ. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J MolSci 2017;18:1321. DOI: 10.3390/ijms18061321
6. Hsu CS , Liu WL, Chao YC, et al. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.HepatolInt 2015; 9:231-42. DOI: 10.1007/s12072-015-9616-2
7. Yalaki S,Yalcin MS. Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years. Niger J ClinPract 2020; 23: 226-31. DOI: 10.4103/njcp.njcp_7_19
8. Koksal AR,Alkim H, Boga S, et al. Effect of entecavir and tenofovirtreatment on noninvasive fibrosis scores: which one is better? Am J Ther2016; 23: e429-38. DOI: 10.1097/MJT.0000000000000203
9. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71:7-33. DOI: 10.3322/caac.21654
10. Jamali R, Hatami N, Kosari F. The Correlation between serum adipokines and liver cell damage in non-alcoholic fatty liver disease. Hepat Mon 2016;16:e37412. DOI: 10.5812/hepatmon.37412
11. Jamali R, Razavizade M, Arj A, Aarabi MH. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22: 5096-103. DOI: 10.3748/wjg.v22.i21.5096
12. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol2017; 67: 370-98. DOI: 10.1016/j.jhep.2017.03.021
13. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol 2016;64:773-780. DOI: 10.1016/j.jhep.2015.11.012
14. Lai M, Afdhal NH. Liver fibrosis determination.GastroenterolClin North Am 2019;48:281-9. DOI: 10.1016/j.gtc.2019.02.002
15. Mak LY, Seto WK, Fung J, Yuen MF.Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Rev ClinPharmacol 2019;12: 109-20. DOI: 10.1080/17512433.2019.1567327
16. Durazzo M, Belci P, Niro G, et al. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis. J Endocrinol Invest 2013;36:600-5. DOI: 10.3275/8883
17. Meng Z, Zhang Y,Wei Z, et al.High serum resistin associates with intrahepatic inflammation and necrosis: an index of disease severity for patients with chronic HBV infection. BMC Gastroenterol 2017; 17:6. DOI: 10.1186/s12876-016-0558-5
18. Tsochatzis E,Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008; 43: 1128-36. DOI: 10.1080/00365520802085387
19. Da Silva TE, Costa-Silva M, Correa CG, et al. Clinical significance of serum adiponectin and resistinlevels in liver cirrhosis. Ann Hepatol 2018;17: 286-99. DOI: 10.5604/01.3001.0010.8659
20. Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J MolSci 2017; 18(7):1392. DOI: 10.3390/ijms18071392
21. Udomsinprasert W, Honsawek S, Poovorawan Y. Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol 2018;10:708-18. DOI: 10.4254/wjh.v10.i10.708
22. Tardelli M, Moreno-Viedma V, Zeyda M, et al. Adiponectin regulates aquaglyceroporin expression in hepatic stellate cells altering their functional state. GastroenterolHepatol 2017;32: 253-60. DOI: 10.1111/jgh.13415
23. You M, Zhou Z, Daniels M, Jogasuria A. Endocrineadiponectin–FGF15/19 axis in ethanol-induced inflammation and alcoholic liver injury. Gene Expr 2018; 18: 103-13. DOI: 10.3727/105221617X15093738210295
Objavljeno
2021/10/26
Broj časopisa
Vol. 41 Br. 2 (2022): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2021 Nerma Čustović, Senija Rašić

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.